Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05650632 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by AbbVie.

Recruiting
Registry status
Phase 1
Development phase
210
Enrollment target
20
Study locations

NCT05650632: Recruiting Phase 1 study of Multiple Myeloma, sponsored by AbbVie.

NCT05650632 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by AbbVie. The registered enrollment target is 210 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05650632, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 1
Development phase
210 participants
Enrollment target
20
Study locations

Study Summary

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B and Arms C \& D. Arm A includes 2 parts: step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of etentamig (ABBV-383). In Part 2, the step-up dose identified in Part 1 (Dose A) will be used followed by the target dose A of etentamig (ABBV-383). In Arm B a flat dose of etentamig (ABBV-383) will be tested. In Arms C \& D, the step-up dose identified in Arm A will be used followed by the target dose of etentamig (ABBV-383) to investigate outpatient administration of etentamig (ABBV-383). Around 210 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 50 sites across the world. Participants will receive etentamig (ABBV-383) as an infusion into the vein in 28 day cycles for approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Primary Outcome

CRS is defined by fever, hypoxia, and hypotension and graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Etentamig (ABBV-383)

Study Locations (20)

Texas

  • Texas Oncology - Central/South Texas /ID# 268563 - Austin
  • Oncology Consultants /ID# 268323 - Houston
  • Texas Oncology - Northeast Texas /ID# 268877 - Tyler

New York

  • Mt Sinai /ID# 251166 - New York
  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167 - New York

North Carolina

  • University of North Carolina /ID# 251203 - Chapel Hill
  • Atrium Health Wake Forest Baptist Medical Center /ID# 251165 - Winston-Salem

Arizona

  • Mayo Clinic Arizona /ID# 251405 - Phoenix

Arkansas

  • Highlands Oncology Group - Springdale /ID# 267742 - Springdale

Colorado

  • Rocky Mountain Cancer Centers - Aurora /ID# 268574 - Aurora

Delaware

  • Medical Oncology Hematology Consultants /ID# 268560 - Newark

Illinois

  • Hope And Healing Cancer Services /ID# 268536 - Hinsdale

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2023-03-21
Est. Completion 2029-08
Phase Phase 1
AbbVie

526 total trials

What NCT05650632 shows while recruiting

NCT05650632 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Etentamig (ABBV-383) is the first listed.

NCT05650632 names 20 study sites across 16 states, led by Texas, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05650632 about?

NCT05650632 is a clinical study titled "A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma". Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come ...

What is the current status of trial NCT05650632?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2023-03-21. Estimated completion is 2029-08.

What conditions does trial NCT05650632 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05650632?

The interventions under investigation include: Etentamig (ABBV-383) (DRUG).

Who is sponsoring clinical trial NCT05650632?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05650632 being conducted?

This trial has 20 study locations across Arizona, Arkansas, Colorado, Delaware, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05650632's enrollment target sits among peer trials

210 106th of 438 higher than 332 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05650632

Source: ClinicalTrials.gov NCT05650632, the US trial registry maintained by the National Library of Medicine. NCT05650632 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.